Drug Trial Radar · NCT07830667
A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
79
Planned (sponsor's estimate)
Start
May 7, 2027
Primary completion
Jun 30, 2033
Study completion Jun 30, 2033
Sponsor
- Lead sponsor
- Children's Oncology GroupResearch network
- Sponsor type
- Research network
- First posted
- Sep 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I/II trial tests the safety, best dose, and effectiveness of CBX-12 in the treatment of pediatric patients (ages 12 months to 30 years) with rhabdomyosarcoma, Ewing sarcoma, or other extracranial solid tumors that have come back after a period of improvement (relapsed) or that do not respond to treatment (refractory). CBX-12 is a conjugate drug made of a peptide linked to a drug called exatecan. Upon administration, the peptide portion of CBX-12 gets inserted into the membrane of tumor cells and then exatecan is released into the tumor cells. Exatecan inhibits deoxyribonucleic acid replication in tumors cells, leading to tumor cell death. CBX-12 may be a safe and effective treatment option for pediatric patients with relapsed or refractory rhabdomyosarcoma, Ewing sarcoma, or other solid tumors.
Conditions
- Recurrent Childhood Ewing Sarcoma
- Recurrent Childhood Malignant Solid Neoplasm
- Recurrent Childhood Rhabdomyosarcoma
- Recurrent Ewing Sarcoma
- Recurrent Extracranial Malignant Solid Neoplasm
- Recurrent Rhabdomyosarcoma
- Refractory Childhood Ewing Sarcoma
- Refractory Childhood Malignant Solid Neoplasm
- Refractory Childhood Rhabdomyosarcoma
- Refractory Ewing Sarcoma
- Refractory Extracranial Malignant Solid Neoplasm
- Refractory Rhabdomyosarcoma
Interventions
Archive Sample RetrievalProcedure
Ancillary studies
Biospecimen CollectionProcedure
Undergo collection of bone marrow and blood samples
pH Low Insertion Peptide-exatecan Conjugate CBX-12Drug
Given IV
Radiologic Imaging ProcedureProcedure
Undergo radiologic imaging
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) (part A phase 1 dose escalation)Time frame: During cycle 1 of part A (dose escalation phase; cycle length = 21 days)
- Recommended phase 2 dose (part A phase 1 dose escalation)Time frame: During cycle 1 of part A (dose escalation phase; cycle length = 21 days)
- Incidence of adverse events (part A phase 1 dose escalation)Time frame: During cycle 1 of part A (dose escalation phase; cycle length = 21 days)
- Pharmacokinetics (part A phase 1 dose escalation)Time frame: During cycle 1 of part A (dose escalation phase; cycle length = 21 days)
- Objective response rate (part B phase 2 dose expansion)Time frame: Up to 60 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.